15 November 2017
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
Oxford BioDynamics presents latest immunotherapy data at the NIH Biomarker Consortium Cancer Steering Committee Annual Symposium, in Washington, DC
EpiSwitchTM technology shows consistent profile of predictive biomarkers for response to immune checkpoint inhibitor therapy
Oxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, presented its latest results at the annual meeting of the Foundation for National Institute for Health (FNIH) Biomarker Consortium Cancer Steering Committee, held in Washington, DC on 6-7 November 2017.
In the session dedicated to immune-oncology biomarkers, Dr A. Akoulitchev, Chief Scientific Officer of OBD, presented the results from three independent studies which showed a consistent profile of epigenetic markers for response to immune checkpoint inhibitor therapies, including anti-PD-L1 therapy Keytruda (Pembrolizumab) and several other anti-PD-L1 assets in two disease indications.
Blind validation of an independent cohort of base line patients treated with an anti-PD-L1 therapeutic showed that OBD's EpiSwitch™ technology could predict response to treatment with a 83% positive predictive value (PPV). The biological relevance of identified epigenetic regulatory biomarkers for immunotherapy was strongly supported by their role in T-cell reinvigoration, survival, and proliferation to tumour burden.
It was also shown that a sub-group of the predictive EpiSwitch™ markers for response to treatment, identified and verified in over 57 patients, were associated to genes which are downstream of Interferon gamma stimulation. Another subgroup of biomarkers revealed high concordance with regulatory controls of MHC II receptors, known to play critical role in response to anti-PD-1 therapy. Full scope of the patient cohorts analysed by OBD will exceed 180 patients.
Further implications of EpiSwitchTM based approaches to patient stratifications were also discussed, including exclusion of patients with hyper progression and other side effects to immunotherapy.
The Biomarkers Consortium is a public-private biomedical research partnership managed by the FNIH that endeavours to discover, develop, and seek regulatory approval for biological markers, known as biomarkers, to support new drug development, preventive medicine, and medical diagnostics.
The Steering Committees are responsible for identifying and moving forward promising pre-competitive biomarkers projects for implementation by The Biomarkers Consortium, as well as overseeing each individual project under its purview. The members of each Steering Committee represent a variety of sectors, including academia, government, industry and not-for-profit/advocacy organisations. OBD is represented at the Steering Committees covering Cancer, Inflammation & Immunity, and Neuroscience by Dr Claudio Carini, an Advisor to OBD and a member of the Company's Scientific Advisory Panel.
Christian Hoyer Millar, CEO of Oxford BioDynamics, commented:
"We are delighted with the progress and consistent quality of biomarker data that our EpiSwitch™ platform has been able to deliver in these immunotherapy studies. The immunotherapy biomarker programme has developed into a high value area of interest for OBD and we are committed to offering quick and robust practical solutions for patient stratifications for all the therapy programmes we are working on.
We have been actively expanding our intellectual property footprint, and with our technology demonstrating consistent practical solutions, we see immunotherapy as a strategic line of biomarker development for our Company, which we believe has the potential to further improve clinical outcomes and the standard of patient care in this area.
We believe that being among a network of many reputable companies and institutions will be beneficial as we continue to progress towards our strategic aim of becoming the industry standard for chromosome conformations and biomarkers in genome architecture."
For further details contact:
Oxford BioDynamics Plc |
|
+44 (0)1865 518910 |
Christian Hoyer Millar, CEO |
|
|
Paul Stockdale, CFO |
|
|
|
|
|
FTI Consulting |
|
+44 (0)20 3727 1000 |
Financial Public Relations Advisor |
|
|
Julia Phillips |
|
|
Brett Pollard |
|
|
Natalie Garland-Collins |
|
|
|
|
|
Stifel Nicolaus Europe Limited |
|
+44 (0)20 7710 7600 |
Nominated Advisor and Broker |
|
|
David Arch |
|
|
Jonathan Senior |
|
|
Peter Lees |
|
|
Ben Maddison |
|
|
|
|
|
Shore Capital |
|
+44 (0)20 7408 4090 |
Joint Broker |
|
|
Stephane Auton |
|
|
Edward Mansfield |
|
|
|
|
|
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a revenue‐generating biotechnology company focused on the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.
The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.
